Evolution of the Average Target: Virbac

Evolution of the Target Price: Virbac

Changes in Analyst Recommendations: Virbac

b541750f06ef1cedfbea9e62f328.OybLkL__NJfSBdDTKuiCDozWcoAW40hzkMQEEUvq70w.dnCB_I-KQMaQbealX4a6eO-7KNpwzhc_oJExdD2Pwg5OVajZ2Zl_9JpwnQ~9be05e46bf6bbfaa4fb6cd4ebc983c85
15/07 Where would AI lead Pharma in the long run? Alphavalue
11/05 Virbac continues decline despite positive recommendation Zonebourse
18/04 Virbac: 2026 starts on strong footing Alphavalue
19/03 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
18/03 Virbac in the green following results and outlook Zonebourse
21/01 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
20/01 Stifel Raises Price Target on Virbac Zonebourse
20/01 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
18/10/25 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/09/25 The day the Fed resumed its rate cuts Zonebourse
15/09/25 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
18/07/25 Virbac: A healthy Q2 impresses the markets Alphavalue
04/07/25 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/07/25 Virbac: Oddo BHF upgrades stock Zonebourse
17/04/25 Virbac: brokers' advice following quarterly results Zonebourse
16/04/25 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/04/25 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/04/25 Virbac: Stifel still buying after Q1 results Zonebourse
18/03/25 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/03/25 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/03/25 Virbac: Stifel raises its recommendation Zonebourse
18/01/25 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
17/01/25 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT
04/11/24 Virbac: Stifel lowers its target price for the stock Zonebourse
19/10/24 Virbac: Market’s anxiety over the Q3 miss was not warranted Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+27.95%
+54.94%
+16.86%
+117.96%
+21.07%
+13.13%
- +38.01%
+27.32%
+25.7%
+44%
Average +38.70%
Weighted average by Cap. +45.23%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
320.00EUR
Average target price
412.00EUR
Spread / Average Target
+28.75%
High Price Target
440.00EUR
Spread / Highest target
+37.50%
Low Price Target
361.00EUR
Spread / Lowest Target
+12.81%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue Abhishek Raval
ODDO BHF
TP ICAP Midcap
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
320.00EUR
Average target price
412.00EUR
Spread / Average Target
+28.75%

Quarterly revenue - Rate of surprise